TEM vs VEEV Stock Comparison: AI Score, Valuation, Performance and Upside
Tempus AI is an earlier-stage, faster-growing precision medicine data company building a genomics and AI-driven dataset that is not yet consistently profitable, while Veeva Systems is a mature, highly profitable life sciences software leader with an entrenched CRM and content management franchise. The better stock depends on whether an investor prefers Tempus's higher-growth, data-driven healthcare AI thesis or Veeva's proven, cash-generative SaaS model.
Use this TEM vs VEEV comparison to weigh earlier-stage healthcare AI data growth against mature, profitable life sciences software compounding. Tempus offers more speculative upside tied to its genomic data moat and pharma partnerships; Veeva offers durable, already-profitable exposure to life sciences digital operations.
VEEV holds the edge across 4 of 5 key metrics in this comparison. VEEV leads on both 1-year return (+8.93%) and forward P/E quality (27.41x vs -2577.61x for TEM), a relatively favorable combination of momentum and valuation. On fundamentals, TEM is growing revenue faster (21.60%), while VEEV maintains the higher operating margin (29.64%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +7.74% for TEM and +4.76% for VEEV.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe Tempus's proprietary genomic and clinical dataset can become a durable competitive moat
- Want exposure to the intersection of AI, genomics, and precision medicine as a long-term secular theme
- Are comfortable with pre-consistent-profitability risk in exchange for higher growth potential
- Value diversified revenue from both diagnostics and pharma data licensing
- Want an already-profitable, high-margin SaaS leader with an entrenched life sciences customer base
- Prefer lower business-model risk than an earlier-stage healthcare AI/data company
- Value strong free cash flow generation and a long track record of product expansion
- Are comfortable with more moderate growth as the core CRM market matures
| Metric | TEM | VEEV |
|---|---|---|
| AI scorei | 33.6 | 56.5 |
| AI ranki | #2058 | #230 |
| Latest closei | $71.13 | $313.03 |
| 1M returni | +3.31% | +17.41% |
| 3M returni | +32.73% | +58.60% |
| 6M returni | +30.71% | +86.67% |
| 1Y returni | -22.61% | +8.93% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | TEM | VEEV |
|---|---|---|
| 1Y ago | $7.81K (-21.9%) started 2025-10-16 | $10.69K (+6.9%) started 2025-10-16 |
| 5Y ago | $17.67K (+76.7%) started 2024-06-14 | $10.08K (+0.8%) started 2021-10-18 |
| 10Y ago | $17.67K (+76.7%) started 2024-06-14 | $82.44K (+724.4%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | TEM | VEEV |
|---|---|---|
| Market capi | $11.18B | $45.45B |
| Trailing P/Ei | N/A | 46.10 |
| Forward P/Ei | -2577.61 | 27.41 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 8.29 | 11.02 |
| Analyst targeti | $66.73 | $294.07 |
| Target upsidei | +7.74% | +4.76% |
| Metric | TEM | VEEV |
|---|---|---|
| Revenue growthi | 21.60% | 17.60% |
| Earnings growthi | N/A | 39.50% |
| EPS growthi | N/A | +39.50% |
| FCF margini | -6.53% | +36.37% |
| Operating margini | -20.11% | 29.64% |
| Profit margini | -17.77% | 29.34% |
| ROIC proxyi | -67.44% | 14.42% |
| Return on equityi | -67.44% | 14.42% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 3.58 | 0.92 |
| Debt/equityi | 324.58 | 2.04 |
| Current ratioi | 3.30 | 5.46 |
| Quick ratioi | 3.01 | 5.36 |
Over the past year, TEM and VEEV have moved weakly in the same direction (correlation of 0.28), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | TEM | VEEV |
|---|---|---|---|
| 1Y | Growthi | -21.85% | +6.93% |
| CAGRi | -21.89% | +6.95% | |
| Volatilityi | 74.07% | 43.09% | |
| Sharpe ratioi | -0.03 | 0.26 | |
| Sortino ratioi | -0.05 | 0.41 | |
| Max drawdowni | 55.06% | 49.37% | |
| Current drawdowni | 23.06% | 0.00% | |
| Avg drawdowni | 34.40% | 27.64% | |
| Ulcer Indexi | 36.93% | 31.69% | |
| Max daily dropi | 13.85% | 9.77% | |
| Max wkly dropi | 20.36% | 16.81% | |
| 5Y | Growthi | +76.72% | +0.82% |
| CAGRi | +27.58% | +0.16% | |
| Volatilityi | 97.04% | 39.56% | |
| Sharpe ratioi | 0.68 | 0.09 | |
| Sortino ratioi | 1.08 | 0.13 | |
| Max drawdowni | 59.76% | 53.54% | |
| Current drawdowni | 31.11% | 3.76% | |
| Avg drawdowni | 33.31% | 34.46% | |
| Ulcer Indexi | 36.85% | 36.57% | |
| Max daily dropi | 19.23% | 16.24% | |
| Max wkly dropi | 37.12% | 21.64% | |
| 10Y | Growthi | +76.72% | +724.41% |
| CAGRi | +27.58% | +23.50% | |
| Volatilityi | 97.04% | 38.89% | |
| Sharpe ratioi | 0.68 | 0.62 | |
| Sortino ratioi | 1.08 | 0.93 | |
| Max drawdowni | 59.76% | 55.69% | |
| Current drawdowni | 31.11% | 8.20% | |
| Avg drawdowni | 33.31% | 22.72% | |
| Ulcer Indexi | 36.85% | 28.69% | |
| Max daily dropi | 19.23% | 16.24% | |
| Max wkly dropi | 37.12% | 21.64% |
| Category | TEM | VEEV |
|---|---|---|
| Company | Tempus AI, Inc. | Veeva Systems Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Health Information Services |
| Core business | Precision medicine company combining genomic sequencing, clinical data, and AI-driven analytics to help physicians and pharmaceutical companies make data-informed treatment and drug-development decisions, monetizing through diagnostic testing and data-licensing partnerships. | Provider of cloud-based software for the life sciences industry, including customer relationship management (Veeva CRM) and content/quality management (Veeva Vault), used by pharmaceutical and biotech companies to manage regulatory, clinical, and commercial operations. |
| Investor focus | Revenue growth across diagnostics and data-licensing segments, path to profitability, expansion of pharma data partnerships, and growth of its proprietary genomic and clinical database. | Subscription revenue growth, customer retention and expansion within the life sciences vertical, profitability and free cash flow margins, and progress of newer product lines beyond core CRM. |
- Large and growing proprietary dataset combining genomic, clinical, and outcomes data creates a potential data moat
- Dual revenue streams from diagnostic testing and data licensing to pharmaceutical partners diversify the business model
- Positioned at the intersection of AI, genomics, and precision medicine — a high-growth secular healthcare theme
- Dominant, entrenched position in life sciences CRM and content management software with high switching costs
- Consistently profitable, high-margin SaaS business model with strong free cash flow generation
- Long track record of successful product expansion (Vault, Compass data, clinical products) within its core vertical
- Continued path to sustained profitability amid high research, sales, and data infrastructure investment
- Reimbursement and regulatory risk associated with diagnostic testing revenue
- Competitive risk from other genomics and precision medicine data companies pursuing similar pharma partnerships
- Growth deceleration risk as its core life sciences CRM market matures and penetration increases
- Customer concentration within the pharmaceutical and biotech industry ties growth to that sector's spending cycles
- Competitive risk from broader enterprise CRM and data platforms attempting to enter life sciences
Compare more than two at a time
This page is a fixed writeup on TEM and VEEV. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside TEM and VEEV, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.